Abstract
With the discovery of the therapeutic activity of peptides, they have emerged as a promising class of anti-cancer agents due to their specific targeting, low toxicity, and potential for high selectivity. In particular, as peptide-drug conjugates enter clinical, the coupling of targeted peptides with traditional chemotherapy drugs or cytotoxic agents will become a new direction in cancer treatment. To facilitate the drug development of cancer therapy peptides, we have constructed DCTPep, a novel, open, and comprehensive database for cancer therapy peptides. In addition to traditional anticancer peptides (ACPs), the peptide library also includes peptides related to cancer therapy. These data were collected manually from published research articles, patents, and other protein or peptide databases. Data on drug library include clinically investigated and/or approved peptide drugs related to cancer therapy, which mainly come from the portal websites of drug regulatory authorities and organisations in different countries and regions. DCTPep has a total of 6214 entries, we believe that DCTPep will contribute to the design and screening of future cancer therapy peptides.
Similar content being viewed by others
Background & Summary
Cancer is a leading cause of death and a significant barrier to increasing life expectancy worldwide1. Cancer treatment has improved in the past few decades, but chemotherapy remains the mainstay of cancer treatment. Multidrug resistance is a major problem associated with anticancer chemotherapy2,3. Data show that 90% of cancer deaths can be attributed to multidrug resistance4. Due to structural differences with small-molecule compounds, bioactive peptides have received much attention and are believed to be alternative candidates for multidrug-resistant cancer therapy5,6,7.
Anticancer peptides (ACPs) are biologically active peptides with antitumor activities that exist widely in a variety of organisms, including mammals, amphibians, insects, plants, and microorganisms. ACPs have many advantages in the treatment of tumours, such as low molecular weight (compared to protein-based therapy), simple structure, high anticancer activity, high selectivity, fewer side effects, easy modifications, and less possibility to cause resistance8,9. Although ACPs have been extensively studied, its mechanism of action is not fully understood. At present, the known mechanisms of ACPs mainly include inhibition of tumour cell proliferation or migration10,11, inhibition of tumour blood vessel formation12, causing cancer cell lysis13, and induction of cancer cell apoptosis14. In addition, peptides can also serve as a targeted therapeutic agent that can target and directly bind specific cancer cells or cancer related biomarkers, and can also serve as a peptide carrier linked to traditional anticancer drugs15,16.
Although the enormous potential of peptides in cancer therapeutics, there is a relative scarcity of dedicated databases specifically storing cancer therapy peptides information. Most of the ACPs information is dispersed in bioactive peptide databases, such as DRAMP17, APD18, DBAASP19, HORDB20, CPPsite21, and SATPdb22, which mainly focus on antimicrobial peptides or hormones. The CancerPPD23 database is a known database for annotating ACPs and anticancer proteins; however, its data have not been updated since 2015. Many antimicrobial peptide databases also store information about the anticancer activity of some antimicrobial peptides, but it does not contain detail annotation of ACPs. For example, they did not fully provide information on cancer cells or molecular targets of ACPs, nor do they include peptide drugs. Therefore, we constructed an open, comprehensive database of cancer therapy peptides, DCTPep, that not only includes traditional ACPs, but also peptides with targeted effects on cancer therapeutics. DCTPep can be freely accessed and downloaded from http://dctpep.cpu-bioinfor.org/.
Developing targeted therapies that selectively act on cancer cells has always been an ideal approach for cancer treatment. A promising targeted therapy is drug conjugates, which involve linking targeting carriers with chemotherapy drugs or cytotoxic agents through a linker, such as antibody-drug conjugates (ADCs) and peptide-drug conjugates (PDCs)24. Currently, the most common drug conjugates used in cancer treatment in clinical practice are ADCs. However, with the increasing presence of peptides in clinical, PDCs has also emerged. PDCs have the potential to overcome the limitations of ADCs, such as smaller molecular weight and ease of synthesis25. Nowadays, only two PDCs, 177 Lu-dotatate (DCTPepD0013) and Melflufen (DCTPepD0108), have been approved for clinical cancer treatment, of which Melflufen being withdrawn from the market by the FDA. However, there are still many PDCs in cancer clinical development or about to enter clinical trials. The potential of PDCs cannot be ignored. Peptides play a crucial role as carriers in PDCs. Therefore, DCTPep not only focuses on collecting ACPs but also emphasizes the collection of cancer targeted peptides. The carrier peptides in PDCs include cell-penetrating peptides (CPP) and cell-targeting peptides (CTP)26. The classification field in the database also follows a similar category, including cell-penetrating peptides, cancer-targeting peptides, and targeted peptide conjugates.
Figure 1 and Table 1 presents the comparative results of DCTPep datasets with ACP datasets in other peptide databases. Compared to DBAASP, CancerPPD and SATPdb, DCTPep possesses over 3000 unique entries. DCTPep provides a vast amount of cancer therapy peptide data, including clinically relevant peptide drugs curated in the drug library, filling the gaps in existing data and offering assistance in the design and screening of novel cancer therapeutic peptides. Particularly, the targeted peptide data will offer more options for PDC design. In order to better understand the mechanism of action of cancer therapy peptides, we have added target annotations and collected over 60 targets for these peptides that are not included in other ACPs databases. The dataset is freely available to all via the web without the need to login or registration and is not password protected. We believe that DCTPep will become a valuable resource for the development of novel bioactive peptides, particularly in the field of cancer therapeutics.
Methods
Data collection and compilation
In order to develop DCTPep, extensive searches were conducted on published articles, patents, and public databases. The data of DCTPep was stored in two sub libraries: peptide library and drug library. The inclusion criteria for the peptide library in the DCTPep were as follows: 1. The sequence of amino acids is reported; 2. Mature peptide sequences without precursor and signal regions; 3. The length of the sequence does not exceed 100 amino acids; 4. Peptides that exhibit anticancer/antitumor activity or target specific molecules/biomarkers overexpressed in cancer cells; 5. Cell-penetrating peptides that can enhance the delivery of drugs into cancer cells. The inclusion criteria for drug library were similar to those for peptide library: 1. Peptides and their derivatives or amino acid derivatives related to cancer treatment; 2. Entered clinical research or approved by FDA, EMA or HC.
To collect peptide data, keywords were used to search in academic search engines such as Google Scholar, Web of Science, PubMed, and Google Patents. The keywords included “ACP”, “antiangiogenic peptides”, “cancer therapy peptide”, “cancer targeted peptide”, and “peptide conjugates”. After collecting research papers, patents, and clinical research literature, data were manually extracted. In addition to manually extracting information of cancer therapy peptide from literature, also included other information related to peptides (such as three-dimensional structures) in UniProt27, PDB28, and other databases. The physicochemical information of peptides is calculated using Expasy Protparam server (https://web.expasy.org/protparam/, accessed on March 2024) and SciDBMaker29.
The data of drug library mainly originated from the portal websites of drug regulatory authorities and organisations in several countries and regions. In addition, it was supplemented by the drug databases DrugBank30, PubChem31, NCI Thesaurus32 and Global Substance Registration System (GSRS)33. By entering keywords such as “peptides and their derivatives”, “amino acids and their derivatives”, and “anticancer” into the aforementioned website or database, relevant information can be found.
Structural prediction and evaluation
Due to the difficulties in experimental determination of peptide and protein structures, most of the peptides lack experimental determined structures. AlphaFold34 was used to predict the potential 3D structures of DCTPep peptides. Default structure parameters for AlphaFold prediction were used: peptide was modeled as a monomer; Multiple sequence alignment (MSA) information databases: full_dbs (all gene databases)34. Each peptide generates 5 structures, and the structure with the highest score is selected based on predicted local distance difference test (pLDDT)34. To evaluate the reliability of AlphaFold predicted peptide structures, 30 peptides with experimental determined structures were selected and their structures were predicted by AlphaFold. The differences between predicted structure and experimentally determined structure were calculated by Root-Mean-Square Deviation (RMSD)35. Given two conformations, α and β of N residues, let rα and rβ be the respective coordinates of their residues at position i, for 1, …, N. RMSD between α and β as Eq. (1):
Where Q is the unitary rotation matrix that optimally aligns the vectors. Disulfide bonds are also considered to see if AlphaFold can correctly predict the disulfide bonds. Whatcheck36 and Procheck37 are used to assess the quality of the predicted structures. Whatcheck36 evaluates multiple parameters such as bond lengths, bond angles, and torsion angles of the input structure. Procheck37 assesses the stereochemical quality of the input structure and provides various graphical outputs. Ramachandran plot38 is used to evaluate the rationality of the structure, where peptide bond dihedral angles Ψ(psi) and Φ(phi) combinations are expected to located in most favored regions and allowed regions (core regions) in the plot. Ideally, a protein structure should have over 90% dihedral angles Φ-Ψ of residues in these core regions37.
Data Records
The datasets of DCTPep are available at Figshare39 and contains the following files: All_information (annotation information table for storing peptide library entries), peptideactivity (activity information annotation of peptide library entries), peptidedrug (annotation information table for storing active Ingredients of drug library entries), marketpeptide (approved drug preparations information annotation of drug library entries), clinicalpeptide (clinical peptide information annotation of drug library entries), peptide_library_all (peptide library data stored in Fasta format) and prediction pdb (compressed packets for storing predicted structures). The architecture of the DCTPep is shown in Fig. 2. DCTPep contains a total of 6214 peptide entries, of which 6106 are stored in the peptide library and 108 are stored in the drug library (DCTPepD), involving over 60 targets and over 380 cancer cell lines.
Table 2 displays detailed annotation information of the data in the peptide library. Each entry in the peptide library consists of the following sections: general information, activity information, structural information, physicochemical information, literature information, and links. The peptides in the peptide library included cancer therapeutic peptides such as traditional ACP and cancer targeted peptides. Low cytotoxicity and hemolytic activity are also important criteria for developing peptide-based drugs. Therefore, in addition to anticancer activity and targets, activity information also includes cytotoxicity and hemolytic activity. All annotation information is manually extracted from the literature, and corresponding paper or patent source information is provided. The physicochemical information is calculated by Protparam and SciDBMaker29. For the same peptide, the emphasis of the information recorded in different databases may vary. Therefore, DCTPep provides corresponding peptide entry codes in other peptide databases.
The data in the drug library includes peptide drugs that have been approved or are in clinical research stage. Table 3 shows detailed annotation information for drug library data. Each entry consists of four sections: general information, structural information, external codes, and drug approval. The external codes provide identification codes for drug entries in other public databases, allowing users to obtain more comprehensive information on related entries from other sources. Approved drug formulations and clinical information can be found in the drug approval section. A total of 28 approved anticancer peptide drugs and 80 peptides in various clinical trial stages are included in the drug library.
Technical Validation
Alphafold demonstrated unprecedented accuracy in 14th Critical Assessment of protein Structure Prediction (CASP14)34. The study conducted by McDonald et al.40 also indicated that AlphaFold can accurately predict peptides with α-helices, β-sheets, and rich in disulfide bonds. To evaluate the accuracy of AlphaFold, 30 ACPs with experimentally determined structures were predicted by AlphaFold.
Table 4 and Fig. 3 displays the comparison results between predicted structures and experimental structures, including RMSD and disulfide bond positions. The results indicate that the predicted structures have high accuracy. The deviations between the predicted and experimental structures are small, with an average of Cα (α-carbon atom) RMSD value is 1.621 Å. For structures containing disulfide bonds, AlphaFold can accurately predict the positions of the disulfide bonds. Some of the predicted structures of peptides can be directly obtained from the AlphaFold Protein Structure Database41, for example, AF-P82393-F1 (DCTPep00006) and AF-P80400-F1 (DCTPep00097).
pLDDT is an important parameter for assessing the confidence of predictions34. While using pLDDT alone to define the accuracy of predicted peptide structures may not be entirely accurate, it can still reflect their accuracy to some extent. DCTPep integrates the Mol* Viewer42 to display the predicted structures, where the pLDDT of each residue can be visualized in the structure43 (Fig. 4).
The quality assessment of the predicted structures was performed using Whatcheck36 and Procheck37 (Table 5), and the results indicate that the predicted structures are reliable. The average error rate of Whatcheck is 11.52%, which is at a relatively low level. In the Ramachandran plot generated by Procheck, the average core regions occupancy rate is 95.11%, only the DCTPep00623 has a low occupancy rate of core regions. The average disallowed regions occupancy rate is 0.26%, only DCTPep00267 has one residue present in the disallowed regions. These errors are within an acceptable range.
Code availability
DCTPep can be freely accessed at http://dctpep.cpu-bioinfor.org/. The data are stored in the Figshare repository available at https://doi.org/10.6084/m9.figshare.25796353.v1.
References
Bray, F., Laversanne, M., Weiderpass, E. & Soerjomataram, I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 127, 3029–3030 (2021).
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S. & Baradaran, B. The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv. Pharm. Bull. 7, 339–348 (2017).
Alfarouk, K. O. et al. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int. 15, 71 (2015).
Bukowski, K., Kciuk, M. & Kontek, R. Mechanisms of Multidrug Resistance in Cancer Chemotherapy. Int. J. Mol. Sci. 21, 3233 (2020).
Arumugam, V., Venkatesan, M., Ramachandran, S. & Sundaresan, U. Bioactive Peptides from Marine Ascidians and Future Drug Development–A Review. Int. J. Pept. Res. Ther. 24, 13–18 (2018).
O’Brien-Simpson, N. M., Hoffmann, R., Chia, C. S. B. & Wade, J. D. Editorial: Antimicrobial and Anticancer Peptides. Front. Chem. 6, 13 (2018).
Kardani, K. & Bolhassani, A. Antimicrobial/anticancer peptides: bioactive molecules and therapeutic agents. Immunotherapy. 13, 669–684 (2021).
Xie, M., Liu, D. & Yang, Y. Anti-cancer peptides: classification, mechanism of action, reconstruction and modification. Open Biol. 10, 200004 (2020).
Chiangjong, W., Chutipongtanate, S. & Hongeng, S. Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review). Int J Oncol. 57, 678–696 (2020).
Kannan, A., Hettiarachchy, N. S., Marshall, M., Raghavan, S. & Kristinsson, H. Shrimp shell peptide hydrolysates inhibit human cancer cell proliferation: Shrimp shell peptide hydrolysates inhibit cancer cell proliferation. J. Sci. Food Agric. 91, 1920–1924 (2011).
Khamessi, O., Ben Mabrouk, H., ElFessi-Magouri, R. & Kharrat, R. RK1, the first very short peptide from Buthus occitanus tunetanus inhibits tumor cell migration, proliferation and angiogenesis. Biochem. Biophys. Res. Commun. 499, 1–7 (2018).
Gong, F. et al. A Novel Peptide from Abalone (Haliotis discus hannai) to Suppress Metastasis and Vasculogenic Mimicry of Tumor Cells and Enhance Anti-Tumor Effect In Vitro. Mar. Drugs. 17, 244 (2019).
Gajski, G. & Garaj-Vrhovac, V. Melittin: A lytic peptide with anticancer properties. Environ. Toxicol. Pharmacol. 36, 697–705 (2013).
Ren, S. X. et al. FK-16 Derived from the Anticancer Peptide LL-37 Induces Caspase-Independent Apoptosis and Autophagic Cell Death in Colon Cancer Cells. PLoS One. 8, e63641 (2013).
Peyressatre, M., Prevel, C., Pellerano, M. & Morris, M. C. Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors. Cancers (Basel). 7, 179–237 (2015).
Zhang, Y., Wang, C., Zhang, W. & Li, X. Bioactive peptides for anticancer therapies. Biomater Transl. 4, 5–17 (2023).
Shi, G. et al. DRAMP 3.0: an enhanced comprehensive data repository of antimicrobial peptides. Nucleic Acids Res. 50, D488–D496 (2022).
Wang, G., Li, X. & Wang, Z. APD3: the antimicrobial peptide database as a tool for research and education. Nucleic Acids Res. 44, D1087–1093 (2016).
Pirtskhalava, M. et al. DBAASP v3: database of antimicrobial/cytotoxic activity and structure of peptides as a resource for development of new therapeutics. Nucleic Acids Res. 49, D288–D297 (2021).
Zhu, N., Dong, F., Shi, G., Lao, X. & Zheng, H. HORDB a comprehensive database of peptide hormones. Sci. Data. 9, 187 (2022).
Agrawal, P. et al. CPPsite 2.0: a repository of experimentally validated cell-penetrating peptides. Nucleic Acids Res. 44, D1098–1103 (2016).
Singh, S. et al. SATPdb: a database of structurally annotated therapeutic peptides. Nucleic Acids Res. 44, D1119–1126 (2016).
Tyagi, A. et al. CancerPPD: a database of anticancer peptides and proteins. Nucleic Acids Research. 43, D837–D843 (2015).
Alas, M., Saghaeidehkordi, A. & Kaur, K. Peptide-Drug Conjugates with Different Linkers for Cancer Therapy. J Med Chem. 64, 216–232 (2021).
Lindberg, J., Nilvebrant, J., Nygren, P. A. & Lehmann, F. Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy. Molecules. 26 (2021).
Hoppenz, P., Els-Heindl, S. & Beck-Sickinger, A. G. Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies. Front Chem. 8, 571 (2020).
Consortium, U. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res. 49, D480–D489 (2021).
Bittrich, S. et al. RCSB Protein Data Bank: improved annotation, search and visualization of membrane protein structures archived in the PDB. Bioinformatics. 38, 1452–1454 (2022).
Hammami, R., Zouhir, A., Naghmouchi, K., Ben Hamida, J. & Fliss, I. SciDBMaker: new software for computer-aided design of specialized biological databases. BMC Bioinf. 9, 121 (2008).
Wishart, D. S. et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 46, D1074–D1082 (2018).
Kim, S. et al. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 49, D1388–D1395 (2021).
Sioutos, N. et al. NCI Thesaurus: a semantic model integrating cancer-related clinical and molecular information. J Biomed Inform. 40, 30–43 (2007).
Peryea, T. et al. Global Substance Registration System: consistent scientific descriptions for substances related to health. Nucleic Acids Res. 49, D1179–D1185 (2021).
Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature. 596, 583–589 (2021).
Betancourt, M. R. & Skolnick, J. Universal similarity measure for comparing protein structures. Biopolymers. 59, 305–309 (2001).
Hooft, R. W., Vriend, G., Sander, C. & Abola, E. E. Errors in protein structures. Nature. 381, 272 (1996).
Laskowski, R. A., MacArthur, M. W., Moss, D. S. & Thornton, J. M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Cryst. 26, 283–291 (1993).
Ramachandran, G. N., Ramakrishnan, C. & Sasisekharan, V. Stereochemistry of polypeptide chain configurations. Journal of molecular biology. 7, 95–99 (1963).
Sun, X. DCTPep, the data of cancer therapy peptides. Figshare https://doi.org/10.6084/m9.figshare.25796353.v1 (2024).
McDonald, E. F., Jones, T., Plate, L., Meiler, J. & Gulsevin, A. Benchmarking AlphaFold2 on peptide structure prediction. Structure. 31, 111–119.e112 (2023).
Varadi, M. et al. AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 50, D439–D444 (2022).
Sehnal, D. et al. Mol* Viewer: modern web app for 3D visualization and analysis of large biomolecular structures. Nucleic Acids Res. 49, W431–W437 (2021).
Ruff, K. M. & Pappu, R. V. AlphaFold and Implications for Intrinsically Disordered Proteins. J Mol Biol. 433, 167208 (2021).
Acknowledgements
This work was funded by the National Natural Science Foundation of China (grant number 82273834) and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD2014-65). The authors would like to thank for the computational support from the High-Performance Computing Centre at China Pharmaceutical University.
Author information
Authors and Affiliations
Contributions
H.Z. conceived the project; X.S. and N.Z. designed and developed the database; X.S., Y.L. and T.M. extracted and organized data; X.S. and Y.L. tested the database; X.S. and T.M. proofread the database; X.S. written the manuscript; H.Z. reviewed the manuscript; X.L. provided constructive suggestions for the project; H.Z. guide and supervise the project.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Sun, X., Liu, Y., Ma, T. et al. DCTPep, the data of cancer therapy peptides. Sci Data 11, 541 (2024). https://doi.org/10.1038/s41597-024-03388-9
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41597-024-03388-9
- Springer Nature Limited